Personal fitness/health tracking devices that include electrodermal activity sensors enable tracking of vasomotor symptoms (hot flashes). Multiple conditions are associated with vasomotor symptoms. This article describes nighttime tracking of vasomotor symptoms for an individual over a two-year period. This volunteer was a participant in a longitudinal study on volunteers wearing physiological monitors. Personal tracking of vasomotor symptoms will provide new insights on the differences between conditions and impacts on individual's health.
Introduction
Continuous tracking of electrodermal activity (EDA), also known as galvanic skin response (GSR), values with commercial fitness devices for individuals with vasomotor symptoms (hot flashes) provides a path forward for future studies with fine resolution monitoring. This can improve upon the current reliance on the use of personal diaries (Regestein et al., 2015) . There are multiple conditions associated with vasomotor symptoms including menopause/early menopausal transition (Hale et al., 2014) , medications (Quinestrol, tramadol, etc.) , chemotherapy and Tamoxifen, hyperthyroidism, infections (Inflammatory Bowel Disease -IBD, etc.), and more. Multiple studies have characterized hot flashes in premenopausal and menopausal women using self reported methods, laboratory polysomnographic recording, and some specially designed devices (Freedman, 2014) . However, it is difficult for an individual to track and accurately report nighttime vasomotor symptoms without the aid of a physiological monitoring device (Freedman, 2014) . Emerging commercial and custom devices with EDA meters will greatly facilitate the nighttime monitoring of hot flashes for individuals for more informative longitudinal studies of conditions with associated vasomotor symptoms. This report illustrates the potential fine-resolution monitoring of nighttime vasomotor symptoms using commercially available activity-tracking devices with an EDA sensor.
Methods
MIT Lincoln Laboratory conducted a longitudinal study on volunteers wearing physiological monitors (June 15 2014 to October 2 2016). The study protocol and written consent form were reviewed and approved by the MIT Committee on the Use of Humans as Experimental Subjects (COUHES). The commercial devices in the study include the Basis B1 watch and Basis Peak watch monitors for tracking heart rate, sleep with predicted sleep phases (light, deep, and REM -rapid eye movement), activity, skin temperature, and perspiration (EDA/GSR) without the use of electrodes or gel. The Basis B1 and Peak watches are no longer commercially available, but similar devices with EDA/GSR sensors are available.
Vasomotor symptoms started disrupting the sleep of a female volunteer on November 23, 2015, calling attention to their occurrence. After November 23, 2015, the volunteer started personally logging the occurrence of vasomotor symptoms, noting that the recorded EDA signals reflected the logged hot flash intensities and durations. Figure 1 shows data from eight days around this time period. Freedman (Freedman, 1989 ) identified a good agreement between an increase of 2 μS/cm in 30 s time period with volunteer 
Results

Discussion
Longitudinal studies of large numbers of volunteers will provide new foundations for tracking vasomotor symptoms associated with menopause and other conditions. Continuous tracking of EDA values with readily available commercial tracking devices will provide a path forward for future fine-resolution longitudinal studies of conditions associated with vasomotor symptoms. Insights into understanding and treating vasomotor symptoms will be greatly advanced by these longitudinal studies, as the different causes of vasomotor symptoms may vary in intensities and durations. EDA is also reported as a sensitive index of sympathetic nervous system activity (Poh et al., 2010) . In addition, commercial devices with EDA meters will be valuable personal monitoring tools to premenopausal and menopausal women and individuals experiencing vasomotor symptoms.
Data availability
The nighttime EDA values tracked are available in Ricke, Darrell, 2017, "GSR nights", doi: 10.7910/DVN/ONAUUZ, Harvard Dataverse.
Consent
Written informed consent was obtained from the volunteer for the publication of her details.
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The author provides information on a single research study participant who incidentally experienced vasomotor symptoms while testing a physiological monitor in what is presumably a separate study. Changes in electrodermal activity appeared to correlate with self reported night time vasomotor symptoms.
This case report describes the experience of a single volunteer. There are several details missing that would make it easier to understand how the original study was conducted. The scholarship of the manuscript is also incomplete.
The parent study in which the participant with vasomotor symptoms was recruited is inadequately described. If already published, a reference to the study would be helpful. If it not published or is proprietary, basic information about inclusion and exclusion criteria for the parent study is important to provide (age and sex of participants, BMI inclusion/exclusion, if any, comorbidity or medications, for a start). It is curious why the author recorded only night time EDA. Why not perform a subjective, daytime hot flash assessment concurrent with the wearing of the monitor to assess the relationship better? 3.
4.
5.
6.
The presentation would benefit greatly from a more quantitative assessment of the agreement between night time hot flashes that disrupted the participant's sleep and objectively determined hot flashes using the monitor. The Figures do not convey information with sufficient clarity. It appears that two days of EDA data are overlaid, yet we do not know whether these were nights with vasomotor symptoms or not. It appears to be assumed that a rise in EDA means the same thing as a hot flash. How can the author be sure of this? The presentation of two years' data in Figure 2 is Accurate detection and recording of night time vasomotor symptoms while sleeping is difficult to quantify outside of laboratory polysomnographic studies.
The article includes quantitative assessment of sleep impact derived from the Basis watch sleep monitoring: "A review of all sleep time data indicates an increase in sleep interruption minutes as reported by Basis (52/1957=2.9% for EDA range 10-15 μS/cm and 15/311=4.8% for EDA range 15-25 μS/cm compared to 3823/258119=1.5% for EDA < 1 μS/cm)." Inclusion of self-reported sleep quality like Pittsburgh Sleep Quality Index (PSQI) was not included in the original study design, but would have been a nice addition for interested volunteers. Figure 1 illustrates eight nights flanking immediately before and during the first nights that the volunteer became self-aware of vasomotor symptoms occurring. Figure 2 illustrates fluctuations in night time vasomotor symptoms spanning a two-year format in both a heat map and a summary graph with peak EDA measurements. Data are available for download for closer examinations.
The article by Newton et al. evaluates and rejects three monitors as being unsuitable. The article by Bahr et al. describes another device that attaches over the sternum with adhesive hydrogels; removal of this device after a week can cause skin irritations. These articles would be good additional articles to cite.
The reviewer raises the question of subjective symptoms and the drive for treatment-seeking. This article includes only quantified measurements. This volunteer did not seek treatments. In contrast the volunteer felt empowered being able to confirm symptoms with EDA measurements via Basis provided phone and web interfaces to personal measurements.
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